2016 Q2 Form 10-Q Financial Statement
#000156459016024607 Filed on August 22, 2016
Income Statement
| Concept | 2016 Q2 | 2015 Q2 |
|---|---|---|
| Revenue | $10.74M | $7.129M |
| YoY Change | 50.58% | 5.21% |
| Cost Of Revenue | $2.852M | $2.508M |
| YoY Change | 13.72% | 4.37% |
| Gross Profit | $7.883M | $4.621M |
| YoY Change | 70.59% | 5.67% |
| Gross Profit Margin | 73.43% | 64.82% |
| Selling, General & Admin | $8.749M | $4.855M |
| YoY Change | 80.21% | 23.66% |
| % of Gross Profit | 110.99% | 105.06% |
| Research & Development | $3.143M | $2.510M |
| YoY Change | 25.22% | 216.92% |
| % of Gross Profit | 39.87% | 54.32% |
| Depreciation & Amortization | $840.0K | $190.0K |
| YoY Change | 342.11% | 72.73% |
| % of Gross Profit | 10.66% | 4.11% |
| Operating Expenses | $17.70M | $10.02M |
| YoY Change | 76.76% | 40.64% |
| Operating Profit | -$6.968M | -$2.886M |
| YoY Change | 141.44% | 736.52% |
| Interest Expense | $526.0K | -$260.0K |
| YoY Change | -302.31% | -59.38% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$274.0K | -$43.00K |
| YoY Change | 537.21% | -111.75% |
| Pretax Income | -$10.93M | -$3.185M |
| YoY Change | 243.27% | 411.24% |
| Income Tax | -$440.0K | $0.00 |
| % Of Pretax Income | ||
| Net Earnings | -$10.47M | -$3.185M |
| YoY Change | 228.73% | -463.17% |
| Net Earnings / Revenue | -97.53% | -44.68% |
| Basic Earnings Per Share | -$0.77 | -$0.27 |
| Diluted Earnings Per Share | -$0.77 | -$0.27 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 13.57M | 11.84M |
| Diluted Shares Outstanding | 13.57M | 11.84M |
Balance Sheet
| Concept | 2016 Q2 | 2015 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $17.10M | $36.90M |
| YoY Change | -53.66% | 367.09% |
| Cash & Equivalents | $17.14M | $36.89M |
| Short-Term Investments | ||
| Other Short-Term Assets | $1.800M | $700.0K |
| YoY Change | 157.14% | -78.79% |
| Inventory | $8.700M | $731.0K |
| Prepaid Expenses | ||
| Receivables | $4.900M | $1.700M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $32.50M | $40.01M |
| YoY Change | -18.76% | 195.68% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $3.400M | $2.559M |
| YoY Change | 32.86% | 53.69% |
| Goodwill | $12.01M | |
| YoY Change | 0.0% | |
| Intangibles | $6.650M | |
| YoY Change | 0.0% | |
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $200.0K | $0.00 |
| YoY Change | ||
| Total Long-Term Assets | $67.95M | $21.36M |
| YoY Change | 218.12% | 4.37% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $32.50M | $40.01M |
| Total Long-Term Assets | $67.95M | $21.36M |
| Total Assets | $100.5M | $61.37M |
| YoY Change | 63.69% | 80.5% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $3.300M | $1.203M |
| YoY Change | 174.31% | -30.9% |
| Accrued Expenses | $10.90M | $4.200M |
| YoY Change | 159.52% | -25.0% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $18.10M | $2.380M |
| YoY Change | 660.5% | -77.19% |
| Total Short-Term Liabilities | $38.20M | $8.242M |
| YoY Change | 363.48% | -61.15% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $10.07M | $13.39M |
| YoY Change | -24.77% | 60.58% |
| Other Long-Term Liabilities | $11.90M | $28.00K |
| YoY Change | 42400.0% | -99.45% |
| Total Long-Term Liabilities | $10.07M | $13.42M |
| YoY Change | -24.93% | 60.91% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $38.20M | $8.242M |
| Total Long-Term Liabilities | $10.07M | $13.42M |
| Total Liabilities | $68.60M | $24.59M |
| YoY Change | 178.94% | -30.65% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$164.8M | |
| YoY Change | 2.65% | |
| Common Stock | $12.00K | |
| YoY Change | 1100.0% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $31.90M | $36.77M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $100.5M | $61.37M |
| YoY Change | 63.77% | 80.5% |
Cashflow Statement
| Concept | 2016 Q2 | 2015 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$10.47M | -$3.185M |
| YoY Change | 228.73% | -463.17% |
| Depreciation, Depletion And Amortization | $840.0K | $190.0K |
| YoY Change | 342.11% | 72.73% |
| Cash From Operating Activities | -$6.070M | -$1.740M |
| YoY Change | 248.85% | -304.71% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$170.0K | -$370.0K |
| YoY Change | -54.05% | 164.29% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$20.57M | $0.00 |
| YoY Change | -100.0% | |
| Cash From Investing Activities | -$20.73M | -$370.0K |
| YoY Change | 5502.7% | -28.85% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 20.21M | 10.00K |
| YoY Change | 202000.0% | -99.63% |
| NET CHANGE | ||
| Cash From Operating Activities | -6.070M | -1.740M |
| Cash From Investing Activities | -20.73M | -370.0K |
| Cash From Financing Activities | 20.21M | 10.00K |
| Net Change In Cash | -6.590M | -2.100M |
| YoY Change | 213.81% | -169.31% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$6.070M | -$1.740M |
| Capital Expenditures | -$170.0K | -$370.0K |
| Free Cash Flow | -$5.900M | -$1.370M |
| YoY Change | 330.66% | -238.38% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2016Q2 | cdna |
Business Acquisition Deferred Payment Consideration With Interest Accretion
BusinessAcquisitionDeferredPaymentConsiderationWithInterestAccretion
|
5807000 | |
| CY2016Q2 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
3475000 | |
| CY2016Q2 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
11000 | |
| CY2016Q2 | us-gaap |
Revenues
Revenues
|
10735000 | |
| CY2016Q2 | us-gaap |
Cost Of Services
CostOfServices
|
2852000 | |
| CY2016Q2 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
3056000 | |
| CY2016Q2 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-97000 | |
| CY2016Q2 | us-gaap |
Interest Expense
InterestExpense
|
526000 | |
| CY2016Q2 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
3165000 | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
11824993 | ||
| CY2015Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
0 | |
| us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-21654000 | ||
| CY2016Q2 | us-gaap |
Profit Loss
ProfitLoss
|
-10493000 | |
| us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-5457000 | ||
| CY2016Q2 | us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
-23000 | |
| CY2015Q2 | us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
0 | |
| CY2016Q2 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-23000 | |
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-1408000 | ||
| us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
0 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
12768913 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
276000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
733000 | ||
| us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
20567000 | ||
| CY2016Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10470000 | |
| CY2016Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.77 | |
| CY2015Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.27 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.58 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.46 | ||
| CY2016Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
13568120 | |
| CY2015Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
11835405 | |
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
0 | ||
| CY2016Q2 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-11901000 | |
| CY2015Q2 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-3185000 | |
| us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
-23000 | ||
| us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
0 | ||
| CY2016Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-11878000 | |
| CY2015Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-3185000 | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-21631000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-5457000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1097000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
358000 | ||
| us-gaap |
Cost Of Goods Sold Depreciation
CostOfGoodsSoldDepreciation
|
1225000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
812000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
692000 | ||
| cdna |
Amortization Of Deferred Revenue
AmortizationOfDeferredRevenue
|
31000 | ||
| cdna |
Amortization Of Deferred Revenue
AmortizationOfDeferredRevenue
|
59000 | ||
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
56000 | ||
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
450000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
982000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-981000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-236000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
45000 | ||
| us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
-845000 | ||
| us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
108000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-336000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-116000 | ||
| us-gaap |
Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
|
39000 | ||
| us-gaap |
Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
|
367000 | ||
| us-gaap |
Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
|
18000 | ||
| us-gaap |
Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
|
27000 | ||
| us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
2153000 | ||
| us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
274000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-12259000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-2747000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
3943000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-17000 | ||
| cdna |
Debt Assumed As Part Of Acquisition
DebtAssumedAsPartOfAcquisition
|
0 | ||
| us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
0 | ||
| cdna |
Intangible Assets Excluding Goodwill Foreign Currency Translation Gain Loss
IntangibleAssetsExcludingGoodwillForeignCurrencyTranslationGainLoss
|
-1365000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-20843000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-733000 | ||
| us-gaap |
Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
|
0 | ||
| us-gaap |
Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
|
15625000 | ||
| us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
20619000 | ||
| us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
0 | ||
| us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
175000 | ||
| us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
0 | ||
| us-gaap |
Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
|
428000 | ||
| us-gaap |
Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
|
11724000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
9000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
42000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
20375000 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-12744000 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
463000 | ||
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
36431000 | |
| CY2015Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
36894000 | |
| CY2016Q2 | cdna |
Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
|
5700000 | |
| CY2015Q2 | cdna |
Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
|
0 | |
| cdna |
Debt Assumed As Part Of Acquisition
DebtAssumedAsPartOfAcquisition
|
13421000 | ||
| cdna |
Common Shares Issued As Part Of Acquisition
CommonSharesIssuedAsPartOfAcquisition
|
7205000 | ||
| cdna |
Common Shares Issued As Part Of Acquisition
CommonSharesIssuedAsPartOfAcquisition
|
0 | ||
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i) revenue recognition, (ii) the differences between amounts billed and estimated receipts from payers, (iii) the determination of the accruals for clinical studies, (iv) the determination of refunds to be requested by third-party payers, (v) the fair value of assets and liabilities, (vi) inventory valuation, (vii) the valuation of warrants, Series A Preferred, and common stock issued in the Private Placement and Subsequent Financing, (viii) the fair value of contingent consideration in a business acquisition, (ix) the fair value of embedded derivatives, (x) measurement of stock-based compensation expense, (xi) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xii) any impairment of long-lived assets, including in-process technology and goodwill, and (xiii) legal contingencies. Actual results could differ from those estimates.</p></div> | ||
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper, and various bank deposit accounts. As of June 30, 2016, these financial instruments were held in Company accounts at five financial institutions. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also subject to credit risk from its accounts receivable which are derived from revenue earned from AlloMap tests provided for patients located primarily in the U.S. and billed to various third-party payers, and sales of Olerup SSP products to distributors, strategic partners and end customers in Europe, Middle East and Africa, the U.S., and Latin America and other. <font style="color:#000000;">The Company has not experienced any significant credit losses and does not generally require collateral on receivables. </font>For the six months ended June 30, 2016 and 2015, approximately 48% and 50%, respectively, of testing revenue was derived from Medicare. No other payers represented more than 10% of testing revenue for these periods. Product revenue accounted for 20% of total revenue for the six months ended June 30, 2016. At June 30, 2016, Medicare and Aetna accounted for approximately 22% and 10% of accounts receivable, respectively. At December 31, 2015, Medicare and Aetna accounted for approximately 35% and 21% of accounts receivable, respectively. No other payers represented more than 10% of accounts receivable at either June 30, 2016 or December 31, 2015. </p></div> | ||
| us-gaap |
Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration, License and Other Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has generated revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company’s performance obligations under its collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes contingent consideration received from the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved, which the Company believes is consistent with the substance of its performance under its various license and collaboration agreements. The Company did not recognize any revenue connected with milestones during the three and six months ended June 30, 2016 and 2015.</p></div> | ||
| cdna |
Non Controlling Interest Investment
NonControllingInterestInvestment
|
634000 | ||
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
27050000 | |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
501000 | |
| us-gaap |
Finite Lived Intangible Assets Foreign Currency Translation Gain Loss
FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
|
-1170000 | ||
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
25379000 | |
| us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P12Y1M6D | ||
| CY2016Q2 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
38210000 | |
| CY2016Q2 | cdna |
Intangible Assets Excluding Goodwill Accumulated Amortization
IntangibleAssetsExcludingGoodwillAccumulatedAmortization
|
501000 | |
| us-gaap |
Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
|
16786000 | ||
| us-gaap |
Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
|
-719000 | ||
| us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
2 | ||
| CY2016Q2 | us-gaap |
Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
|
28200000 | |
| us-gaap |
Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
|
Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. | ||
| us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | ||
| us-gaap |
Number Of Reporting Units
NumberOfReportingUnits
|
2 | ||
| us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | ||
| CY2016Q2 | cdna |
Collaboration Agreement Outstanding Amount
CollaborationAgreementOutstandingAmount
|
0 | |
| cdna |
Collaboration Agreement Outstanding Amount
CollaborationAgreementOutstandingAmount
|
0 | ||
| CY2015Q2 | cdna |
Collaboration Agreement Outstanding Amount
CollaborationAgreementOutstandingAmount
|
0 | |
| cdna |
Collaboration Agreement Outstanding Amount
CollaborationAgreementOutstandingAmount
|
0 | ||
| CY2016Q2 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | |
| us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | ||
| CY2015Q2 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | |
| us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5406712 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2204050 | ||
| CY2016Q2 | cdna |
Preferred Stock Issued Shares Private Placement
PreferredStockIssuedSharesPrivatePlacement
|
2959300 | |
| CY2016Q2 | cdna |
Preferred Stock Issued Shares Subsequent Financing
PreferredStockIssuedSharesSubsequentFinancing
|
2959300 | |
| CY2014Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
1074000 | |
| CY2015 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
-126000 | |
| CY2015Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
948000 | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
4957000 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
2855000 | ||
| cdna |
Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
|
0 | ||
| CY2015 | cdna |
Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
|
0 | |
| CY2016Q2 | cdna |
Minimum Lender Required Proceeds From Issuance Of Private Placement Offer
MinimumLenderRequiredProceedsFromIssuanceOfPrivatePlacementOffer
|
12000000 | |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
2117000 | |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
13316000 | |
| CY2016Q2 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
7485000 | |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
1175000 | |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
2351000 | |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
2186000 | |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
2117000 | |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
2117000 | |
| CY2015Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
237000 | |
| CY2016Q2 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
1166000 | |
| CY2015Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
529000 | |
| CY2016Q2 | cdna |
Accrued Debt Financing Fees Current
AccruedDebtFinancingFeesCurrent
|
1747000 | |
| CY2015Q4 | cdna |
Accrued Debt Financing Fees Current
AccruedDebtFinancingFeesCurrent
|
0 | |
| CY2016Q2 | cdna |
Accrued Placement And Subsequent Financing Offering Costs
AccruedPlacementAndSubsequentFinancingOfferingCosts
|
339000 | |
| CY2016Q2 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
500000 | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
500000 | ||
| CY2015Q2 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
0 | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
0 | ||
| CY2016Q2 | cdna |
Indefinite Lived Intangible Assets Excluding Goodwill Gross
IndefiniteLivedIntangibleAssetsExcludingGoodwillGross
|
11200000 | |
| CY2015Q4 | cdna |
Accrued Placement And Subsequent Financing Offering Costs
AccruedPlacementAndSubsequentFinancingOfferingCosts
|
0 | |
| CY2016Q2 | cdna |
Accrued Transaction Related Fees Current
AccruedTransactionRelatedFeesCurrent
|
353000 | |
| CY2015Q4 | cdna |
Accrued Transaction Related Fees Current
AccruedTransactionRelatedFeesCurrent
|
589000 | |
| CY2016Q2 | cdna |
Accrued Software Implementation Costs
AccruedSoftwareImplementationCosts
|
315000 | |
| CY2015Q4 | cdna |
Accrued Software Implementation Costs
AccruedSoftwareImplementationCosts
|
0 | |
| CY2016Q2 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
762000 | |
| CY2015Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
0 | |
| CY2016Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
370000 | |
| CY2015Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
89000 | |
| CY2016Q2 | cdna |
Accrued Sample Processing Fees
AccruedSampleProcessingFees
|
478000 | |
| CY2015Q4 | cdna |
Accrued Sample Processing Fees
AccruedSampleProcessingFees
|
426000 | |
| CY2016Q2 | cdna |
Accrued Over Payments And Refunds
AccruedOverPaymentsAndRefunds
|
339000 | |
| CY2015Q4 | cdna |
Accrued Over Payments And Refunds
AccruedOverPaymentsAndRefunds
|
163000 | |
| CY2016Q2 | cdna |
Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
|
1079000 | |
| CY2015Q4 | cdna |
Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
|
756000 | |
| CY2016Q2 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
364000 | |
| CY2015Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
258000 | |
| CY2016Q2 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
53000 | |
| CY2015Q4 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
71000 | |
| CY2016Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1496000 | |
| CY2015Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
540000 | |
| CY2016Q2 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
1003000 | |
| CY2016Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
2026000 | |
| CY2016Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
2033000 | |
| CY2016Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
2051000 | |
| CY2016Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
2016000 | |
| CY2016Q2 | cdna |
Operating Leases Future Minimum Payments Due In Six Years
OperatingLeasesFutureMinimumPaymentsDueInSixYears
|
6000 | |
| CY2016Q2 | cdna |
Operating Leases Future Minimum Payments Due After Six Years
OperatingLeasesFutureMinimumPaymentsDueAfterSixYears
|
1000 | |
| CY2016Q2 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
9136000 | |
| cdna |
Description Of Agreement Expected Expiration Year
DescriptionOfAgreementExpectedExpirationYear
|
The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014. | ||
| CY2013Q2 | cdna |
Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
|
250000 | |
| CY2013Q2 | cdna |
Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
|
344000 | |
| CY2013Q2 | cdna |
Upfront Payment In Cash
UpfrontPaymentInCash
|
387500 | |
| CY2013Q2 | cdna |
Upfront Payment In Cash
UpfrontPaymentInCash
|
503000 | |
| CY2016Q2 | us-gaap |
Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
|
16000 | |
| CY2015Q2 | us-gaap |
Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
|
16000 | |
| us-gaap |
Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
|
31000 | ||
| us-gaap |
Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
|
33000 | ||
| CY2016Q2 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
0 | |
| CY2015Q2 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
89000 | |
| us-gaap |
Royalty Revenue
RoyaltyRevenue
|
100000 | ||
| CY2016Q2 | cdna |
Royalty Revenue Receivable
RoyaltyRevenueReceivable
|
0 | |
| CY2015Q4 | cdna |
Royalty Revenue Receivable
RoyaltyRevenueReceivable
|
0 | |
| CY2015Q1 | us-gaap |
Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
|
20000000 | |
| us-gaap |
Debt Instrument Description Of Variable Rate Basis
DebtInstrumentDescriptionOfVariableRateBasis
|
Draw A bears interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the Lender. | ||
| CY2015Q1 | us-gaap |
Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
|
0.0200 | |
| us-gaap |
Line Of Credit Facility Initiation Date1
LineOfCreditFacilityInitiationDate1
|
2015-01-30 | ||
| us-gaap |
Debt Instrument Maturity Date
DebtInstrumentMaturityDate
|
2018-12-01 | ||
| CY2016Q2 | cdna |
Debt Issuance And Discount Component Of Recognized Debt Liability Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent
|
200000 | |
| CY2015Q4 | cdna |
Debt Issuance And Discount Component Of Recognized Debt Liability Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent
|
200000 | |
| CY2016Q2 | cdna |
Debt Issuance And Discount Component Of Recognized Debt Liability Non Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent
|
100000 | |
| CY2015Q4 | cdna |
Debt Issuance And Discount Component Of Recognized Debt Liability Non Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent
|
100000 | |
| cdna |
Prepayment Penalty
PrepaymentPenalty
|
0.00 | ||
| us-gaap |
Debt Instrument Description
DebtInstrumentDescription
|
The Company agreed to issue to the Lender warrants to purchase shares of the Company’s common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche. | ||
| CY2015Q1 | cdna |
Estimated Fair Value Of Warrants
EstimatedFairValueOfWarrants
|
90000 | |
| us-gaap |
Default Longterm Debt Description Of Violation Or Event Of Default
DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault
|
Upon the occurrence of an event of default, a default interest rate of an additional 5.00% may be applied to the outstanding loan balances, and the Lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. | ||
| cdna |
Percentage Of Default Interest Payment
PercentageOfDefaultInterestPayment
|
0.0500 | ||
| CY2016Q2 | us-gaap |
Bridge Loan
BridgeLoan
|
18000000 | |
| us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
2900000 | ||
| CY2016Q2 | cdna |
Accrued Interest On Shareholder Loans
AccruedInterestOnShareholderLoans
|
700000 | |
| CY2016Q2 | cdna |
Long Term Debt Maturities Repayments Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsRemainderOfFiscalYear
|
14502000 | |
| CY2016Q2 | cdna |
Long Term Debt Maturities Repayments In Year Two
LongTermDebtMaturitiesRepaymentsInYearTwo
|
6990000 | |
| CY2016Q2 | cdna |
Long Term Debt Maturities Repayments In Year Three
LongTermDebtMaturitiesRepaymentsInYearThree
|
6990000 | |
| CY2016Q2 | cdna |
Long Term Debt Maturities Repayments
LongTermDebtMaturitiesRepayments
|
28482000 | |
| CY2016Q2 | cdna |
Debt Discount And Issuance Costs
DebtDiscountAndIssuanceCosts
|
-275000 | |
| CY2016Q2 | us-gaap |
Long Term Debt
LongTermDebt
|
28207000 | |
| CY2016Q2 | us-gaap |
Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
|
1700000 | |
| CY2016Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
1002507 | |
| cdna |
Securities Purchase Agreement Private Placement Units Description
SecuritiesPurchaseAgreementPrivatePlacementUnitsDescription
|
On April 14, 2016, the Company completed a Private Placement transaction for the offering of 591,860 Units. Each Unit was comprised of: (i) one share of Common Stock, (ii) five shares of Series A Preferred, and (iii) three warrants, each to purchase one share of Common Stock. The purchase price was $23.94 per Unit (the equivalent of $3.99 per share of Common Stock, assuming conversion of the Series A Preferred). | ||
| CY2016Q2 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
591860 | |
| CY2016Q2 | us-gaap |
Sale Of Stock Price Per Share
SaleOfStockPricePerShare
|
23.94 | |
| CY2016Q2 | cdna |
Common Stock Purchase Price
CommonStockPurchasePrice
|
3.99 | |
| CY2016Q2 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
14200000 | |
| CY2016Q2 | us-gaap |
Fees And Commissions Transfer Agent
FeesAndCommissionsTransferAgent
|
1800000 | |
| cdna |
Additional Issued Units
AdditionalIssuedUnits
|
334169 | ||
| CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.01 | |
| CY2015Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.10 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.06 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.62 | ||
| CY2016Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
367000 | |
| CY2015Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
411000 | |
| cdna |
Intersegment Sales
IntersegmentSales
|
0 | ||
| CY2016Q2 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
843000 | |
| CY2015Q2 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
193000 | |
| CY2016Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
2200000 | |
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y6M29D | ||
| CY2016Q2 | cdna |
Income Tax Benefit Due To The Reversal Of Net Deferred Tax Liabilities
IncomeTaxBenefitDueToTheReversalOfNetDeferredTaxLiabilities
|
400000 | |
| cdna |
Income Tax Benefit Due To The Reversal Of Net Deferred Tax Liabilities
IncomeTaxBenefitDueToTheReversalOfNetDeferredTaxLiabilities
|
400000 | ||
| us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
900000 | ||
| CY2016Q2 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
3300000 | |
| CY2016Q2 | cdna |
Intersegment Sales
IntersegmentSales
|
0 | |
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1104000 | ||
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
358000 |
